Ipsen: preliminary data from study on Onivyde

(CercleFinance.com) - Ipsen has presented preliminary data from a phase I/II study of liposomal irinotecan (Onivyde) as a possible first-line treatment for metastatic pancreatic cancer at a conference in Barcelona.


The results indicate that adverse effects occurring during the grade 3 (or more) treatment were observed in 20 out of the 32 patients of the group analysis of patients on 50/60 doses (primary endpoint).

Regarding efficacy, Ipsen states that nearly three quarters of patients (71.9%) achieved disease control in the 16th week, while 34% experienced a response (secondary endpoint).


Copyright (c) 2019 CercleFinance.com. All rights reserved.